Mycophenolate mofetil: A unique immunosuppressive agent

Hood, Kerri; Zarembski, Dawn G.

doi:10.1093/ajhp/54.3.285

Cited by 89 publications

(63 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lymphocytes are more dependent on this pathway than other cells. Therefore, the cytotoxic effect of MMF is through inhibition of proliferation of T and B lymphocytes and by suppression of humoral immune responses by B lymphocytes 22. Furthermore, a number of open label studies of patients with various other immune mediated disorders have reported efficacy with the use of MMF 11 12 14 15 23–25…”

Section: Discussionmentioning

confidence: 99%

Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy

Bedi

Brown

Tong

et al. 2010

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy

Bedi

Brown

Tong

et al. 2010

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

show abstract

“…As an immunosuppressant, mycophenolate mofetil at doses of 1000 mg twice daily has been used widely in the setting of renal transplantation [48]. Lower doses, such as 250 to 500 mg twice daily, may have a less pronounced immunosuppressive effect and may have a role in enhancing antiretroviral therapy.…”

Section: Mycophenolate Mofetilmentioning

confidence: 99%

Management of HIV-infected patients with multidrug-resistant virus

Montaner

Harris

2002

Curr Infect Dis Rep

View full text Add to dashboard Cite

Heavily pretreated HIV-infected patients with multidrug-resistant virus remain a clinical challenge to the treating physician. While the goal of therapy in such patients is still controversial, sustained immunologic and clinical benefit have only been demonstrated with complete suppression of plasma viral load below detectable levels. Expert use of resistance testing may help in the selection of the salvage regimen, and monitoring of plasma drug levels may help optimize the potency and tolerability, especially of complex, multiple drug regimens where adherence remains a critical determinant of treatment outcome. The potential roles of newer agents, adjuvants, treatment interruptions, and immune-based therapies remain under investigation.

show abstract

“…Mycophenolate mofetil is also a new agent introduced in the 1990s and can be used as substitute for azathioprine. It has been demonstrated as a useful agent in the renal transplant population [67], and studies are now underway in assessing its efficacy in the heart transplant population [68]. In laboratory studies, there is some data that suggest it may decrease the incidence of graft coronary artery disease [67][68][69][70].…”

Section: Transplantationmentioning

confidence: 99%

Surgical approaches to dilated cardiomyopathy

Smolens

Bolling

2000

Curr Cardiol Rep

View full text Add to dashboard Cite

Heart failure is one of the leading causes of hospitalization in the United States today. Congestive heart failure is a chronic progressive disease with the common central element being the remodeling of the cardiac chamber associated with ventricular dilation. Secondary mitral regurgitation is a complication of end-stage cardiomyopathy and is associated with a poor prognosis. Historically, these patients were not considered operative candidates due to the high morbidity and mortality in this patient population. Heart transplantation is now considered the standard of treatment for select patients with end-stage heart disease, however, it is only applicable to a small number of patients. In an effort to address this problem, newer and alternative surgical approaches are evolving, including mitral valve annuloplasty, the Batista myoplasty, and cardiomyoplasty. When these operative techniques that alter the shape of the left ventricle are utilized, in combination with optimal medical management for heart failure, survival is improved and patients can avoid or postpone transplantation.

show abstract

Mycophenolate mofetil: A unique immunosuppressive agent

Cited by 89 publications

References 0 publications

Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy

Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy

Management of HIV-infected patients with multidrug-resistant virus

Surgical approaches to dilated cardiomyopathy

Contact Info

Product

Resources

About